

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE
TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Scoping

STA Mirabegron for the treatment of symptoms associated with overactive bladder

The impact on equality has been assessed during this appraisal according to the principles of the NICE Equality scheme.

- | |
|---|
| 1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they? |
|---|

During consultation it was noted that people with overactive bladder whose symptoms have not been controlled with currently available therapies may need to supply their own incontinence pads. For low-income patients, these out-of-pocket expenses represent a higher proportion of their total income.
--

- | |
|---|
| 2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee? |
|---|

The 'Guide to the methods of technology appraisal' states that a technology appraisal should be conducted from an NHS/PSS perspective and costs borne by patients should not be included unless they are reimbursed by the NHS or PSS.
--

All patients have the same treatment choices, irrespective of income and mirabegron would be expected to provide a similar benefit in all socioeconomic groups. Socioeconomic status is a characteristic that is not currently protected under equality legislation. Therefore it is not a specific equality issue, but is a factor which the Committee will be mindful of during the course of the appraisal.
--

3. Has any change to the draft scope been agreed to highlight potential equality issues?

No changes were required.

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the matrix been made?

No further stakeholders have been identified.

Approved by Associate Director (name): Janet Robertson.....
15/08/12

Date: